Data Highlighting Neumedicines’ HemaMax™ to Be Presented at American Society of Hematology Annual Meeting (ASH)

Share Article

Neumedicines to Present Clinical and Scientific Data of HemaMax™, an Investigational Product Being Developed as a Treatment for Multiple Indications in Hematology and Oncology

Neumedicines Inc., a privately held biotechnology company, today announced that data from two abstracts, including one oral presentation, evaluating Neumedicines’ investigational products, will be presented at the 56th American Society of Hematology Annual Meeting between December 6-9 in San Francisco, California. Presentations will include HemaMax™ (recombinant human interleukin-12 or rHuIL-12) data from company-sponsored studies.

"We are excited once again this year to present clinical and scientific data at ASH," said Lena A. Basile, President and Chief Executive Officer for Neumedicines. "The data from these studies being shared underscore our commitment to delivering innovative therapies to patients with serious hematologic diseases around the world."

Clinical and scientific data presented have been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contracts No. HHSO1002000800060C and No. HHSO100201100037C.

Abstracts include:

Abstract #756; Oral; Tuesday, December 9, 8:45 AM PST. Chris Lawrence, PhD. Recombinant Human IL-12 Exerts Differential Effects on Circulating CD56bright and CD56dim NK Cells in Healthy Human Subjects

Abstract #4354; Poster; Monday, December 8, 6:00-8:00 PM PST. Zoya Gluzman Poltorak, PhD, MBA. Association of Hematological Nadirs and Survival in a Non-Human Primate Model of Hematopoietic Syndrome of Acute Radiation Syndrome

A complete listing of abstracts can be found on the ASH Web site at http://www.hematology.org/Annual-Meeting/Abstracts/

About HemaMax™
HemaMax™ (rHuIL-12) holds considerable value and promise playing a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity while also playing a critical role in hematopoietic cell-to-cell signaling. Under the trade name HemaMax™, Neumedicines is also developing rHuIL-12 as a treatment for the hematopoietic syndrome of acute radiation syndrome (HSARS) and as a treatment for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.

About Neumedicines Inc.
Neumedicines Inc., a California corporation, is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches for the treatment of various clinical indications that address unmet clinical and societal needs in the fields of oncology, hematology, and immunology. The company operates from its headquarters and laboratories in Pasadena, California.

Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no assurance that any product in Neumedicines pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

David Morash
Visit website